An Open-Label, Phase 1b Study of SL-172154 (SIRP-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers
Study of SL-172154 in Combination with PLD or MIRV in Patients with Ovarian Cancer
Sponsor: Shattuck Labs
Enrolling: Female Patients Only
IRB Number: AAAU3147
U.S. Govt. ID: NCT05483933
Contact: Reena Vattakalam: 212-342-6895 /
Additional Study Information: The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian cancer. The study drug, SL-172154 is an immunotherapy drug. Immunotherapies are treatments that use your bodys own immune (defense) system to help fight cancer. SL-172154 binds to a protein called CD47 on cancer cells and to a protein called CD40 on immune cells. Pegylated liposomal doxorubicin (PLD), also known by the brand names of Doxil or Caelyx, is a medication that can block a certain enzyme that is involved in cell division and growth; this blocking action may kill cancer cells. PLD is an approved medicine used for the treatment of adults with ovarian cancer whose disease has gotten worse or recurred after a platinum-based chemotherapy. This study is also designed to understand how your body reacts to the study drug (absorbs, distributes, breaks down and gets rid of SL-172154) and the effect of the combination treatment, if any, on ovarian cancer. The study will examine biomarkers (present in your blood sample or tumor biopsy) that may be related to how the study drug is working. This is the fourth study using SL-172154 in humans. As of 23 April 2022, 28 patients with cancer involving solid tumors have been treated with SL-172154 on its own.
Do You Qualify?
Have you been diagnosed with ovarian, fallopian tube or primary peritoneal cancer? Yes No
Has you cancer worsened within 3-6 months after treatment? Yes No
Do you have tissue available from previous surgery? Yes No
Do you have at least one measurable lesion on scans? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Reena Vattakalam